Alzheimer's disease & dementia

MAO is a possible Alzheimer's disease biomarker

Alzheimer's disease affects more than 35 million people, a number that is expected to increase in the coming years. Currently, Alzheimer's diagnoses rely on clinical neuropathologic assessment of amyloid-β (Aβ) peptide ...

Alzheimer's disease & dementia

Dysfunctional endosomes are early sign of neurodegeneration

Writing in the April 11 issue of the Journal of Clinical Investigation, researchers at University of California, San Diego School of Medicine say abnormalities in a protein that helps transport and sort materials inside cells ...

Alzheimer's disease & dementia

Panel of 48 CSF proteins complements existing Alzheimer biomarkers

A panel of 48 proteins in the cerebrospinal fluid (CSF 48 panel) complements existing CSF biomarkers for Alzheimer disease (AD), according to a study published in the Sept. 6 issue of Science Translational Medicine.

Alzheimer's disease & dementia

Researchers identify potential biomarker for AD

Researchers from Boston University School of Medicine (BUSM) report variants in a new gene, PLXNA4, which may increase the risk of developing Alzheimer's disease (AD). The discovery of this novel genetic association may lead ...

page 6 from 7